Related Experiment Video

Updated: Aug 2, 2026

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

9.0K

NGS-Based ctDNA Profiling After the Resistance of Second-Line Osimertinib for Patient with EGFR-Mutated Pulmonary

Dan Li1, DaFu Yang1, SaiQiong Cui1

  • 1The Second Department of Thoracic Medical Oncology, The Second Hospital of Dalian Medical University, Dalian, Liaoning, People's Republic of China.

Oncotargets and Therapy
|July 29, 2021
PubMed

Insights

Osimertinib effectively treats EGFR T790M positive non-small-cell lung cancer. However, acquired resistance mechanisms in lung adenocarcinoma patients treated with osimertinib can be detected using circulating tumor DNA (ctDNA) genotyping.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Osimertinib is a third-generation EGFR tyrosine kinase inhibitor (TKI) used for EGFR T790M positive non-small-cell lung cancer (NSCLC).
  • Acquired resistance to osimertinib is a significant clinical challenge, with heterogeneous underlying mechanisms.
  • Understanding these resistance mechanisms is crucial for improving patient outcomes.

Observation:

  • A case of lung adenocarcinoma with an EGFR L858R mutation is presented.
  • The patient received second-line osimertinib therapy.
  • Multiple osimertinib resistance mechanisms were identified through non-invasive circulating tumor DNA (ctDNA) genotyping.

Findings:

  • Longitudinal ctDNA genotyping revealed acquired resistance mechanisms during osimertinib treatment.
  • Tumor heterogeneity was observed in the development of osimertinib resistance.
  • The study highlights the dynamic nature of resistance in EGFR-mutated NSCLC.

Implications:

  • This case illustrates potential mechanisms of osimertinib resistance during disease progression.
  • Longitudinal monitoring of ctDNA can detect novel acquired resistance and tumor heterogeneity.
  • Non-invasive ctDNA genotyping offers a valuable tool for guiding treatment strategies in NSCLC.
Keywords:
EGFR mutationacquired resistancecirculating tumor DNAlung adenocarcinomaosimertinib

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.1K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.3K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...